Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2009-06-04
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 61
- Registration Number
- NCT00385177
- Locations
- πΊπΈ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
πΊπΈSarah Cannon Research Institute, Nashville, Tennessee, United States
Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC
- Conditions
- Interventions
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2012-10-05
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 70
- Registration Number
- NCT00327340
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
π¨π¦Tom Baker Cancer Centre, Calgary, Alberta, Canada
π¨π¦BC Cancer Agency, Vancouver, British Columbia, Canada
Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
- First Posted Date
- 2005-11-09
- Last Posted Date
- 2009-06-04
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 821
- Registration Number
- NCT00251095
- Locations
- πΊπΈ
Stockton Hematology Oncology, Stockton, California, United States
πΊπΈJoe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States
πΊπΈAlta Bates Comprehensive Cancer Center, Berkeley, California, United States
A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2012-02-06
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 85
- Registration Number
- NCT00138658
- Locations
- π¨π¦
Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada
πΊπΈOregon Health and Science University, Portland, Oregon, United States
πΊπΈCancer Centers of the Carolinas, Greenville, South Carolina, United States
Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast Cancer
- First Posted Date
- 2004-11-15
- Last Posted Date
- 2009-06-04
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 47
- Registration Number
- NCT00096668
- Locations
- π·πΊ
Voronezh Regional Clinical Oncology Center, Voronezh, Russian Federation
π·πΊSemashko Central Clinical Hospital of the Ministry of Transport, Moscow, Russian Federation
π·πΊArkhangelsk Regional Oncology Center, Arkhangelsk, Russian Federation
TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2009-06-04
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 44
- Registration Number
- NCT00077688
- Locations
- πΊπΈ
Cleveland Clinic Foundation, Cleveland, Ohio, United States
πΊπΈUniversity of Maryland Medical Center/Greenbaum Cancer Center, Baltimore, Maryland, United States
πΊπΈUniversity of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States
Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma
- Conditions
- First Posted Date
- 2002-04-25
- Last Posted Date
- 2009-06-04
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 28
- Registration Number
- NCT00034190
- Locations
- π·πΊ
5 Clinical Sites, 3 Cities, Russian Federation
Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium
- Conditions
- First Posted Date
- 2002-04-25
- Last Posted Date
- 2009-06-04
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 27
- Registration Number
- NCT00034177
Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2002-04-24
- Last Posted Date
- 2009-06-04
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 52
- Registration Number
- NCT00034164
Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer
- Conditions
- First Posted Date
- 2002-04-24
- Last Posted Date
- 2009-06-04
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 52
- Registration Number
- NCT00034151